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The melanocortin 1 receptor (MC1R) is a melanocytic Gs protein coupled receptor
that regulates skin pigmentation, UV responses, and melanoma risk. It is a highly
polymorphic gene, and loss of function correlates with a fair, UV-sensitive, and
melanoma-prone phenotype due to defective epidermal melanization and sub-optimal
DNA repair. MC1R signaling, achieved through adenylyl cyclase activation and
generation of the second messenger cAMP, is hormonally controlled by the positive
agonist melanocortin, the negative agonist agouti signaling protein, and the neutral
antagonist β-defensin 3. Activation of cAMP signaling up-regulates melanin production
and deposition in the epidermis which functions to limit UV penetration into the
skin and enhances nucleotide excision repair (NER), the genomic stability pathway
responsible for clearing UV photolesions from DNA to avoid mutagenesis. Herein we
review MC1R structure and function and summarize our laboratory’s findings on the
molecular mechanisms by which MC1R signaling impacts NER.
Keywords: melanocyte, melanoma, MC1R, melanocortin, ASIP, βD3, ATR, DNA repair
MELANOCORTIN RECEPTORS
The melanocortin (MC) receptor family is the smallest member of the class A (rhodopsin-like)
family of G-protein coupled receptors (GPCRs) (Gether, 2000; Montero-Melendez, 2015) and
consists of five members: MC1R, MC2R, MC3R, MC4R, and MC5R with varying tissue expression
and functions. MC1R is found on both melanocytes and leukocytes and its activation promotes UV
resistance and anti-inflammatory signaling, respectively, (Mountjoy et al., 1992). MC2R, cloned
Mountjoy et al. (1992), is found in the adrenal cortex. MC3R, cloned Desarnaud et al. (1994), and
MC4R, cloned Gantz et al. (1993), are both found primarily in the CNS regulating food intake and
sexual function. MC5R, located in skeletal muscle and brain, has an exocrine function (Gantz et al.,
1994a). Sequence homology between the five receptors is only 40–60% which accounts for the lack
of ligand specificity between receptors (Gantz et al., 1993; Yang et al., 2003). This review will focus
on the role of MC1R in melanocytes with an emphasis on ligands, signaling pathways, structure,
and function.
MELANOCORTIN 1 RECEPTOR (MC1R)
The human MC1R is 317 amino acids (Garcia-Borron et al., 2005), and it was originally identified
and cloned by two independent groups Chhajlani and Wikberg (1992) and Mountjoy et al. (1992)
and mapped to chromosome 16q24.3 Gantz et al. (1994b). The receptor is primarily located on
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melanocytes and transformed melanoma cells (Ghanem et al.,
1988; Siegrist et al., 1989, 1994; Donatien et al., 1992). MC1R
protein expression is typically low, with an estimated 700 protein
units expressed per melanocyte and somewhat higher numbers
on melanoma cells (Donatien et al., 1992; Roberts et al., 2006).
The 315 amino acid murine homolog, Mc1r, was also cloned and
identified Mountjoy et al. (1992) and mapped to the extension
locus Robbins et al. (1993). Mice with a mutated extension
locus display a reddish blonde coat color instead of the darkly
pigmented black coat color typically found on the C57BL/6
background, thus providing the first genetic evidence that MC1R
may play an important role in the regulation of pigment (Searle,
1968).
MC1R Structure
Like other GPCRs, MC1R is made up of 7 α-helical
transmembrane (TM) domains with a DRY motif at the
junction of the third TM domain, an intracellular C-terminus
with a palmitoylation site, and an extracellular N-terminus with
an N-linked glycosylation site (Yang, 2011) (Figure 1). Unique
to the MC receptor subfamily compared to other GPCRs is the
lack of one or two cysteines in the first and second extracellular
domains and lack of proline in the fourth and fifth TM domains
(Yang, 2011).
N-terminus and c-terminus
The extracellular N-terminal tail (Figure 1) functions both for
ligand affinity (Chhajlani et al., 1996) and as a signal anchor
(Wallin and von Heijne, 1995; Garcia-Borron et al., 2005). There
is a conserved cysteine residue located at the junction of the
N-terminus and the first TM domain which is absolutely required
for receptor function (Frandberg et al., 2001; Sanchez-Laorden
et al., 2006b). The C-terminus in GPCR often plays a role in
protein trafficking from the endoplasmic reticulum to the plasma
membrane (Schulein et al., 1998; Qanbar and Bouvier, 2003)
and also in receptor interactions with the G protein at the
plasma membrane (Strader et al., 1994). Similar to the other MC
receptors, MC1R has a characteristically short C-terminal tail
that is only 14 amino acids in length (Figure 1). A pentapeptide
present on the C-terminal tail contains the invariant tripeptide
sequence T314, C315, and W317 present in all MC receptors.
The pentapeptide, and specifically the invariant tripeptide,
are required for translocation of the receptor to the plasma
membrane (Sanchez-Mas et al., 2005b). Mutations which disrupt
the pentapeptide or specifically the invariant tripeptide such as
premature termination at R306 (Newton et al., 2000) or deletion
of the terminal pentapeptide (Sanchez-Mas et al., 2005b), result
in decreased plasma membrane MC1R expression. Although
C-terminal deletions have detrimental effects, additional amino
acids on the end of the C-terminus do not appear to affect MC1R
function. A splice variant exists with an additional 65 amino
acids that displays similar pharmacology to the unspliced protein
(Tan et al., 1999). In addition to affecting receptor localization
to the plasma membrane, the C-terminus also plays a role in
desensitization and internalization (Pitcher et al., 1998; Luttrell
and Lefkowitz, 2002).
Intracellular and Extracellular Loops
Melanocortin 1 receptor’s intracellular and extracellular loops
(ils and els, respectively) are found between the transmembrane
regions (Figure 1) and have conserved sequences found across
many MC receptors. MC1R els are small compared to most
GPCRs but are critical for basal constitutive signaling activity
(Holst and Schwartz, 2003). Because the els of MC1R interact
with ligands, mutations in this region impact binding affinity
(Chhajlani et al., 1996). El3 in particular appears to play a
critical role in melanocortin affinity through conserved proline
and cysteine residues (Holst and Schwartz, 2003). El3 interacts
with TM6 and TM7 which are also required for ligand-receptor
binding, and it is believed that C267 and C275 in el3 form
disulfide bonds between TM6 and TM7 affecting the tertiary
structure of the receptor (Frandberg et al., 2001; Holst and
Schwartz, 2003; Garcia-Borron et al., 2005).
Similarly, MC1R ils are important for binding of the Gs
protein and have sites for phosphorylation that affect signal
regulation, internalization, and receptor cycling (Strader et al.,
1994). Il1 is important for normal activation, and mutations
of this domain increase MC1R signaling activity as seen in the
tobacco mutation (S69L in mouse; S71 in human). Six mutations
have been reported in il1, four of which cause a loss of signaling
function (Robbins et al., 1993). As is characteristic for class A
GPCRs, the tripeptide 141 DRY 143 located at the interface
of il2 and TM3 is required for MC1R function (Schioth et al.,
1999). Additionally, there are putative protein kinase A (PKA)
and protein kinase C phosphorylation sites in il2 of both human
and mouse (and il3 in mouse), however, neither PKA nor PKC
has been shown to phosphorylate MC1R to date (Garcia-Borron
et al., 2005).
MC1R Oligomerization
Like many other GPCRs, oligomerization of MC1R is
functionally important for modulation of ligand binding,
coupling efficiency, desensitization, and trafficking through
the endoplasmic reticulum (Sanchez-Laorden et al., 2006a).
MC1R undergoes constitutive dimerization without a ligand
binding requirement (Mandrika et al., 2005; Sanchez-Laorden
et al., 2006a) at the level of the ER (Sanchez-Laorden et al.,
2006a). MC1R homo-dimerization is dependent upon both
covalent and non-covalent interactions rather than a coiled-coil
mechanism, mediated by four inter-subunit disulfide bonds at
C35, C267, C273, and C275 or by domain swapping. Disruption
of any disulfide bond abolishes MC1R function, however, only
C35 is required for MC1R to travel from the ER to the plasma
membrane. Although mutation of C35 prevents translocation of
MC1R to the plasma membrane, the protein can still dimerize,
therefore dimerization is not sufficient for ER to plasma
membrane transport (Sanchez-Laorden et al., 2006a).
Dimerization of heterogeneous receptors can have a dramatic
effect on MC1R signaling. Dimerization between mutant and
wild-type MC1R proteins can cause a dominant negative
effect (Sanchez-Laorden et al., 2006a) similar to that reported
in dimerization of mutant MC4R with wild-type MC4R
(Biebermann et al., 2003). Similarly, dimerization between wild
type and a mutant MC1R unable to translocate to the surface
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FIGURE 1 | Melanocortin 1 receptor (MC1R) gene and protein structures. (A) The human MC1R locus (cytogenetic location: 16q24.3) encodes a seven
transmembrane protein that is highly polymorphic. (B) The mature MC1R protein is a Gs-protein coupled receptor (GPCR) that spans the membrane seven times.
Extracellular and transmembrane domains engage MC1R ligands while intracellular and transmembrane domains regulate adenylyl cyclase interactions and signaling.
of the cell also resulted in dose-dependent dominant negative
inhibition of wild-type MC1R cell surface localization (Sanchez-
Laorden et al., 2006a). Conversely, coupling with wild type
GPCR can partially rescue function of mutant GPCR via
exchange of defective domains (Breitwieser, 2004). Co-expression
of two MC1R mutants with mutations in different domains may
similarly rescue function through complementation, however,
rescue was not observed if mutations were in the same
domain (Sanchez-Laorden et al., 2006a). MC1R dimerization
characteristics could therefore impact melanocortin signaling
and play an important role in individuals with inherited
polymorphisms in the MC1R protein.
MC1R Desensitization
Like other GPCRs, MC1R desensitization and internalization
represent major mechanisms whereby its function can
be regulated (Pitcher et al., 1998). Multiple members of
the melanocortin receptor family undergo homologous
desensitization including murine Mc2R (Baig et al., 2001),
murine Mc4r (Shinyama et al., 2003), and both murine
Mc1R and human MC1R (Sanchez-Mas et al., 2005a). MC1R
undergoes homologous desensitization following short exposure
to its positive agonist, α-MSH in a PKA independent and G
protein coupled receptor kinase (GRK) dependent manner.
Following agonist stimulation, GRKs phosphorylate GPCRs
resulting in receptor decoupling from the G protein and
subsequent internalization (Benovic et al., 1985; Hausdorff
et al., 1990). MC1R desensitization is dependent upon GRK2
and GRK6, however, internalization only requires GRK6
phosphorylation of T308 and S316 on the C-terminus (Sanchez-
Laorden et al., 2007). Studies conducted in primary human
melanocytes, however, demonstrated that GRK expression
varies between individuals (Swope et al., 2012). In addition,
MC1R desensitization is further mediated via β-arrestins
(ARRB). ARRBs bind the phosphorylated receptor and prevent
the receptor from coupling to the G protein and target the
receptor for internalization (Attramadal et al., 1992). Recently,
ARRB2 but not ARRB1 has been shown to play a role in
receptor desensitization and internalization (Abrisqueta et al.,
2013).
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Melanocortin Signaling and cAMP
Melanocortin 1 receptor is complexed to the heterotrimeric G
protein. Following activation with agonistic ligands the Gαs
protein dissociates from MC1R and stimulates adenylyl cyclase
activity which cleaves ATP to generate the second messenger
cAMP (Figure 2). In melanocytes, increased cAMP levels lead
to a host of downstream signaling events including activation of
effector proteins such as cAMP-dependent protein kinase (PKA)
(Neves et al., 2002; Dorsam and Gutkind, 2007). In this manner
MC1R signaling activates various signaling cascades within the
cell. In melanocytes, cAMP induction leads to increased melanin
synthesis (Suzuki et al., 1997; Abdel-Malek et al., 2014) and
resistance to UV injury through enhanced antioxidant defenses
and acceleration of nucleotide excision repair (NER) (Kokot
et al., 2009; Song et al., 2009; Kadekaro et al., 2010, 2012;
Abdel-Malek et al., 2014; Jarrett et al., 2014). The dissociated
Gαβ protein can also modify intracellular signaling including
the mitogen-activated protein kinase family which affects a
multitude of signaling pathways (further reviewed by Dorsam
and Gutkind, 2007). MC1R, like other GPCRs, displays some
degree of ligand independent basal signaling (Chalmers and
Behan, 2002; Milligan, 2003). This has been demonstrated for
both human MC1R (Mas et al., 2003) and murine Mc1r (Jackson
et al., 2007), human MC3R, human MC4R, and murine Mc5r
(Nijenhuis et al., 2001). Genetic proof of basal MC1R signaling
is evident in Pomc1 knockout mice which are incapable of
generating melanocortins which are the major agonists of MC1R.
In contrast to Mc1r-defective strains such as extension, POMC-
null mice maintain a dark coat color, suggesting Mc1r has
constitutive ligand independent activity (Bennett and Lamoreux,
2003).
MC1R and Pigmentation
There are two major types of pigment present in the skin,
the darkly pigmented eumelanin and the red/yellow sulfated
pheomelanin. Eumelanin is chemically inert and is highly
photoprotective by absorbing UV radiation (Kaidbey et al., 1979;
Scherer and Kumar, 2010) and oxidants (Hoogduijn et al.,
2004). In contrast, pheomelanin is much less efficient at blocking
penetration of UV radiation into the skin and can promote
UV-induced cellular damage by contributing to free radical
and oxidative injury (Thody et al., 1991; Mitra et al., 2012).
MC1R signaling is a major determinant for the amount and
type of melanin pigments synthesized by melanocytes, regulating
both basal pigmentation and the UV induced tanning response
(D’Orazio et al., 2006). MC1R signaling increases eumelanin
synthesis, the ratio of eumelanin-to-pheomelanin (Hunt et al.,
1995), and enhances melanosome transfer to enhance melanin
deposition in keratinocytes (Virador et al., 2002).
Both eumelanin and pheomelanin derive from the sequential
cyclization and oxidation of the amino acid tyrosine (Figure 3)
(Ito, 2003). The first two biosynthetic steps are shared between
the two pathways: the conversion of tyrosine to DOPA
and then to DOPAquinone by the enzyme tyrosinase.
Eumelanogenesis and pheomelanogenesis diverge after
formation of DOPAquinone. Other enzymes beside tyrosinase
are needed for melanin synthesis including dopachrome
tautomerase and tyrosinase-related protein 1. Defects in many
pigment enzymes yield hypomelanotic phenotypes such as
albinism (Baxter and Pavan, 2013). Pheomelanin production is
dependent upon the incorporation of a cysteine and retention of
sulfur after the synthesis of DOPAquinone, which may explain
why mature pheomelanin pigments are reddish/yellow rather
than dark brown/black as eumelanin is. Although the control
of the pigment switch between eumelanin and pheomelanin is
regulated by multiple factors including the pH of the cellular
milieu and the levels of tyrosinase (Burchill and Thody, 1986;
Ancans et al., 2001), the presence of a functional MC1R is
required for effective synthesis of eumelanin. Since eumelanin
absorbs UV radiation, the more eumelanin the skin has, the more
protected it is from UV damage.
MC1R Variants
Melanocortin 1 receptor is a highly polymorphic protein, and
in humans many of the loss-of-function variants are associated
with the “red hair color” (RHC) phenotype (Valverde et al., 1995;
Box et al., 1997; Smith et al., 1998; Abdel-Malek et al., 2014).
Individuals with a dysfunctional MC1R may have decreased
eumelanin synthesis leading to fair skin and an increased
sensitivity to UV exposure (Smith et al., 1998; Palmer et al., 2000;
Landi et al., 2005). Degree of MC1R function correlates with
the extent of pigmentation phenotype in individuals with RHC
variants (Beaumont et al., 2007), and the effects of MC1R on basal
pigmentation can be seen in both humans and murine models.
Murine coat color is heavily influenced by MC1R signaling
as clearly evident by variations in coat color associated with
MC1R mutations such as the extension locus (Figure 4). Mice
with the recessive yellow mutation (mutation of the extension
locus) produce a non-functional MC1R and exhibit a blonde
pheomelanotic coat color as a result (Robbins et al., 1993).
Conversely, an increase in MC1R activity found in either the
somber (constitutive active receptor) or tobacco (hyperactive
receptor) mutation is associated with an increase in eumelanin
synthesis and a darker coat color (Robbins et al., 1993) although
no gain of function mutations have been identified in the human
MC1R gene. The effect of MC1R signaling on basal pigmentation
can be further seen in the lethal yellow mutation which affects
an MC1R ligand rather than MC1R directly. Mice with the lethal
yellow mutation have a blonde pheomelanotic coat color due to
the ubiquitous overexpression of the negative agonist murine
homolog of ASIP (ASP) inhibiting which diminishes basal Mc1r
activity (Lovett et al., 1987).
Adaptive Tanning
The ability of the skin to respond to UV radiation by increasing
melanin production is dependent on the functionality of MC1R.
The adaptive pigmentation pathway represents a major innate
protective mechanism by which the skin prevents further
damage from ultraviolet radiation and is dependent upon MC1R
signaling. UV radiation causes DNA damage to keratinocytes
in the epidermis of the skin and the subsequent increased
expression of the POMC protein in a p53 dependent manner
(Cui et al., 2007). Cleavage of POMC by proconvertase 1
and 2 leads to the generation of the positive agonist α-MSH
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FIGURE 2 | Melanocortin – MC1R signaling axis. Melanocortins (α-MSH, ACTH) are produced basally by the pituitary and induced in the skin after UV injury.
Binding of these melanocortin ligands to MC1R promotes critical UV-resistance physiologic changes in melanocytes and protects the skin from UV damage. Upon
binding melanocortins, MC1R activates adenylyl cyclase and stimulates cAMP production. In turn, a variety of downstream effector pathways including induction of
the CREB and Mitf transcription factor networks and an increase in the activity of PKA takes place. Expression of a variety of enzymes including tyrosinase (TYR) and
dopachrome tautomerase (DCT) involved in melanin biosynthesis is increased and melanin production is up-regulated. Melanin produced in organelles termed
melanosomes, is transferred to neighboring keratinocytes and in this way a UV-protective layer of pigment in the epidermis is established to enhance the skin’s ability
to resist further UV injury. Importantly, melanocytic genomic stability is also enhanced through improved DNA repair. In the absence of a functional melanocortin
signaling axis, these pathways are blunted, the skin is under-melanized and melanocytes accumulate more UV mutations as a result of ineffective DNA repair. In this
way, individuals with inherited defects in MC1R signaling are at heightened risk for melanoma.
(Benjannet et al., 1991). Binding of α-MSH to MC1R leads to
the activation of adenylyl cyclase and promotes the generation
of cAMP (Kadekaro et al., 2003; Millington, 2006). cAMP
accumulation promotes the activation of PKA leading to the
phosphorylation of the cAMP responsive binding element
(CREB). CREB functions as a transcription factor causing the
upregulation of microphthalmia transcription factor (MITF).
MITF functions as a master transcription factor and leads to
the increased expression of multiple pigment dependent enzymes
including tyrosinase (Levy et al., 2006).
MC1R and Pigment-independent UV Protection
Besides its role in regulating melanocyte pigment production,
MC1R is a critical determinant of cellular genome maintenance
pathways (Abdel-Malek et al., 2014). Melanocortins augment
melanocyte anti-oxidant defense mechanisms and diminish free
radical injury in melanocytes (Kokot et al., 2009; Song et al.,
2009; Kadekaro et al., 2012). MC1R signaling also plays a critical
role in the ability of melanocytes to recover from UV damage,
particularly with respect to damage to genomic DNA. UV causes
direct damage to pyrimidine bases within DNA that promote
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FIGURE 3 | Melanin synthesis. There are two main types of melanin: the dark brown/black UV-protective eumelanin and the red/blonde sulfated pheomelanin
pigment. Each is derived from progressive cyclization and oxidation of the amino acid tyrosine. Tyrosinase, the rate-limiting enzyme for melanogenesis, catalyzes the
first two stages of melanin biosynthesis. When MC1R is functional and cAMP levels are high, melanocytes produce eumelanin preferentially. In contrast, when MC1R
is dysfunctional and cAMP levels are low, cysteine is incorporated and pheomelanin is made instead. Important pigment enzymes which cause hypopigmentary
phenotypes when defective include tyrosinase (TYR), dopachrome tautomerase (DCT), and tyrosinase related protein-1 (TRP1). Complexion and UV resistance are
mainly determined by the amount of eumelanin in the skin.
mutagenesis if not cleared from the genome. The NER pathway is
the major means by which cells remove UV photoproducts from
genomic DNA (reviewed in Scharer, 2013 and Shah and He, 2015)
(Scharer, 2013; Shah and He, 2015).
Nucleotide excision repair
Nucleotide excision repair is the major genome maintenance
pathway by which cells remove bulky DNA lesions that
distort the DNA double helical structure including UV induced
photoproducts (6,4 photoproducts and cyclobutane dimers). The
NER pathway involves the coordinated action of multiple factors
that recognize, excise, and repair damaged nucleotides. There
are two types of NER - global genome nucleotide excision
repair (GG-NER) and transcription coupled nucleotide excision
repair (TC-NER). They differ in the initial stages of damage
recognition, ultimately converging on a common repair pathway.
TC-NER is invoked when transcription is stalled by nucleotide
lesions in actively transcribed genes (Mellon et al., 1987; Mu and
Sancar, 1997; Sugasawa et al., 1998, 2001). TC-NER is mediated
by Cockayne syndrome B (CSB) and Cockayne syndrome A
(CSA) proteins which are recruited to helical distortions that
have caused RNA polymerase to stall (Mellon et al., 1987;
Venema et al., 1991; Donahue et al., 1994; Mu and Sancar, 1997;
Kamiuchi et al., 2002). In GG-NER, xeroderma pigmentosum
complementation group C (XPC) and HR23B heterodimerize
and scan the genome for helical distortions (Sugasawa et al.,
1998, 2001). After damage recognition, TFIIH, a multiprotein
complex composed of nine proteins, is recruited. TFIIH contains
the helicases XPB and XPD which function in the 3′-5′ and 5′-
3′ directions, respectively, (Gerard et al., 1991). The helicases
unwind approximately 20–30 nucleotides surrounding the DNA
lesion creating two unprotected single strand sequences. RPA
and XPA are recruited to stabilize the open DNA conformation
(Tapias et al., 2004; Park and Choi, 2006) followed by the
endonucleases ERCC1-XPF and XPG which remove the damaged
base (Mu and Sancar, 1997; Houtsmuller et al., 1999). Polymerase
δ and ε in combination with proliferating cell nuclear antigen
replace the gap using the undamaged complementary strand for
fidelity (Shivji et al., 1995; Cleaver, 2005; Shah and He, 2015). In
this way, NER efficiently repairs UV photoproducts and prevents
UV mutagenesis.
MC1R signaling and NER
Individuals with defective MC1R signaling are prone to UV
induced skin cancer not only because they have decreased
pigmentation but also because they have a blunted DNA repair
response. We and others have reported that activation of MC1R
and the subsequent cAMP signaling cascade are major regulators
of NER kinetics and efficiency independent of pigmentation
(Figure 5) (Kadekaro et al., 2005, 2010; Smith et al., 2008;
Jagirdar et al., 2013; Jarrett et al., 2014; Swope et al., 2014). cAMP
signaling directly impacts how long UV photodamage persists in
melanocytes (Hauser et al., 2006; Abdel-Malek et al., 2009), and
repair of photodamage in the skin of K14-Scf mice is much more
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FIGURE 4 | Melanocortin 1 receptor controls coat color in C57BL/6
mice. C57BL/6 mice with wild type (functional) Mc1r exhibit a eumelanotic
phenotype, whereas congenic animals defective for Mc1r, such as extension
mice, exhibit a pheomelanotic coat color. Shown are Mc1rE/E (wt) and
Mc1re/e (extension) age-matched animals along with C57BL/6 Tyrc2j/c2j
animals in either the Mc1rE/E (wt) or Mc1re/e (extension) background in which
neither eumelanin nor pheomelanin can be made because of defective
tyrosinase function (Jarrett et al., 2014). Note that these animals express the
K14-Scf transgene resulting in retention of interfollicular epidermal
melanocytes and pigmentation of the skin in addition to the fur.
robust when Mc1r is functional or when pharmacologic agents
are topically applied to the skin that induce cAMP signaling
(Jarrett et al., 2014).
Although it has been known for a decade that MC1R signaling
accelerates NER kinetics (Abdel-Malek et al., 2006), the molecular
mechanisms by which the phenomenon occurs have only recently
begun to be elucidated and appear to be complex. Acceleration
of repair of photo damage has been shown to be dependent
upon both the nuclear receptor subfamily 4 group A member
2 (NR4A2) and ataxia telangiectasia mutated and Rad3 related
(ATR) signaling pathways (Smith et al., 2008; Jagirdar et al., 2013;
Jarrett et al., 2014). MC1R signaling leads to the induction of
the NR4A2 which translocates to sites of photodamage in a p38
and poly ADP ribose polymerase (PARP) dependent manner.
The NR4A2/PARP complex colocalizes with the DNA damage
proteins XPC and XPE at sites of DNA damage. Data suggests
that NRFA2 may play a role in promoting chromatin relaxation
to promote DNA repair (Smith et al., 2008; Jagirdar et al., 2013).
Recently, we reported that enhancement of NER by cAMP
is dependent on a post-translational modification of ATR
protein. Specifically, we found that MC1R stimulation by
melanocortins or pharmacological cAMP induction caused
PKA to phosphorylate ATR at S435. This event promoted
enhanced binding to the NER factor XPA in the nucleus and
together pS435-ATR and XPA localized to UV photodamage
in an accelerated and robust manner. Without PKA-mediated
phosphorylation of ATR on S435, we observed no enhancement
of NER in melanocytes. Therefore we concluded that MC1R
signaling regulates genomic stability through this ATR-
dependent mechanism (Jarrett et al., 2014). In subsequent work,
we found that the MC1R agonists α-MSH or ACTH stimulated
PKA-mediated ATR phosphorylation and NER whereas the
MC1R negative agonist ASIP and the neutral antagonist
βD3 inhibited the pathway, suggesting that melanocyte genomic
stability and susceptibility to UV mutagenesis may be hormonally
influenced (Jarrett et al., 2015).
Activation of MC1R has also been shown to facilitate repair
via an increase in DNA damage response proteins. Treatment
with α-MSH leads to an increase in XPC and γH2AX levels
promoting formation of DNA repair complexes in primary
human melanocytes (Swope et al., 2014). There is also a
concomitant increase in DNA repair gene expression dependent
upon MC1R signaling (Kadekaro et al., 2010). In addition,
MC1R signaling also promotes the return to homeostasis via
p53 signaling. MC1R activation promotes the phosphorylation
of p53 at S15 in an ATR and DNA-PK dependent fashion
leading to activation of wild-type p53 induced phosphatase 1 and
degradation of γH2AX (Kadekaro et al., 2012; Swope et al., 2014).
HORMONAL REGULATION OF MC1R
Melanocortin 1 receptor signaling is complex and dynamic,
with signaling heavily influenced by receptor interactions with
melanocortins, agouti signaling protein (ASIP), or β-defensin 3
(βD3). Melanocortins enhance MC1R signaling, ASIP inhibits
MC1R signaling directly, and the neutral antagonist βD3
blunts melanocortin-induced signaling by competing with MC1R
agonists for MC1R binding (Figure 6). The major melanocortin
for MC1R, α-MSH, functions to increase cAMP levels after
binding to MC1R whereas binding of ASIP to MC1R competes
with α-MSH binding to prevent melanocortin activation and
results in a decrease in basal cAMP levels. Binding of βD3 to
MC1R does not affect basal cAMP levels, however, it functions
as a competitive inhibitor and interferes with binding of either
α-MSH or ASIP.
Melanocortins
There are four endogenous melanocortin ligands: α-MSH,
β-MSH, γ-MSH, and adrenocorticotropic hormone (ACTH).
Melanocortins are derived as cleavage products of the pro-
opiomelanocortin (POMC) protein (Wintzen and Gilchrest,
1996) (Figure 7), and each has varying receptor binding
affinities across the MC family. The POMC gene contains
three exons and two introns with the bioactive peptides
present in exon 3 (Wintzen and Gilchrest, 1996). POMC
is processed by proconvertase 1 to generate ACTH, the
N-terminal fragment, and beta-lipotropin (β-LPH). Further
cleavage of ACTH by proconvertase 2 generates corticotropin-
like intermediate peptide (CLIP) and α-MSH. Cleavage of the
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FIGURE 5 | Melanocortin 1 receptor signaling and melanocyte genomic integrity. MC1R signaling promotes genomic stability through multiple mechanisms.
MC1R activation induces translocation of NR4A2 to the nucleus in a p38 and PARP1 dependent manner where it co-localizes with XPC and XPE at sites of UV
induced DNA damage. MC1R activation also leads to elevated levels of XPC and γH2Ax promoting the formation of DNA repair complexes. Levels of γH2AX are
regulated by Wip1 downstream of ATR and DNA-PK mediated phosphorylation of p53 at S15. In addition, PKA activation promotes the phosphorylation of ATR at
S435. pS435-ATR complexes with XPA in the nucleus. Following phosphorylation of XPA, the complex translocates to sites of UV induced DNA damage to
accelerate and enhance nucleotide excision repair (NER).
N-terminal fragment by proconvertase 2 generates γ-MSH.
Cleavage of β-LPH generates γ-LPH and β-endorphin (Wintzen
and Gilchrest, 1996) which is active at opiate receptors in the skin.
The UV-dependent β-endorphin production and the resultant
opiate “high” is believed to contribute to UV-seeking behavior
and an increase in analgesic threshold due to opioid dependence
(Fell et al., 2014). POMC expression and processing is induced
in both keratinocytes and melanocytes following UV exposure,
leading to the secretion of MC1R ligands α-MSH and ACTH
(Schauer et al., 1994; Chakraborty et al., 1996) in a p53 dependent
manner (Cui et al., 2007).
ACTH and α-MSH are the two major melanocortins for
MC1R (Abdel-Malek et al., 2000). ACTH was first identified in
Smith (1930), and α-MSH (first termed simply MSH prior to
the discovery of β- and γ-MSH) was identified in the porcine
pituitary Lerner and Lee (1955). α-MSH is expressed in both
human melanocytes and keratinocytes (Chakraborty et al., 1996),
and was first shown to bind to murine and human melanoma
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FIGURE 6 | Melanocortin 1 receptor ligand interactions. Three major
MC1R ligands are α-MSH, ASIP, and βD3. The melanocortin α-MSH functions
as a positive agonist to increase cAMP levels downstream of MC1R. ASIP is a
potent negative agonist that decreases basal MC1R signaling and interferes
with melanocortin-induced cAMP upregulation. βD3 is thought to act as a
neutral antagonist of MC1R, blocking the interactions with either
melanocortins or ASIP but having little signaling impact independently. Each
ligand appears to function as a competitive inhibitor for the others with only
one able to bind to MC1R at any given time. Please note that although not
shown in this diagram, ACTH’s ability to agonize MC1R is roughly the same as
that of α-MSH.
cells via a high affinity receptor Siegrist et al. (1989) and Solca
et al. (1989). α-MSH binding to normal human melanocytes was
demonstrated Donatien et al. (1992) and De Luca et al. (1993) by
two independent investigators.
All melanocortin ligands have an HFRW motif required for
receptor binding that contributes to the generalized ability for
melanocortins to interact with more than one melanocortin
receptor, albeit with different affinities. Binding to MC2R,
however, also requires an additional motif, KKRRP, which is
only present in ACTH. Therefore only ACTH can bind to
MC2R (Mountjoy et al., 1992; Dores, 2009). Both MC1R (Abdel-
Malek et al., 2000; Sanchez-Mas et al., 2004) and MC4R (Gantz
et al., 1993) bind ACTH and α-MSH with similar affinities
and each binds β- and γ-MSH with lower affinity. Similarly,
MC5R binds α-MSH with the highest affinity followed by β-MSH,
ACTH, and γ-MSH in order of decreasing affinity (Gantz et al.,
1994a). Agonists interact with extracellular loops of melanocortin
receptors as well as charged and aromatic residues in the TM
fragments (Garcia-Borron et al., 2005). Specifically, the arginine
of the melanocortin HFRW pharmacophore core interacts with
E94 (TM2), D117, and D121 (TM3). Similarly, aromatic residues
near the extracellular side of melanocortin receptor TM regions
4, 5, and 6 interact with aromatic residues of the melanocortin
pharmacophore (Yang et al., 1997).
Agouti Signaling Protein
The human agouti signaling protein is a 132 amino acid MC1R
ligand encoded by the agouti locus on chromosome 20q11.2 with
85% homology to the murine protein (Miller et al., 1993; Kwon
et al., 1994; Wilson et al., 1995). ASIP functions as a competitive
MC1R inhibitor, efficiently preventing α-MSH binding to MC1R
and inhibiting MC1R activation (Blanchard et al., 1995; Suzuki
et al., 1997). Binding of ASIP and α-MSH to MC1R are mutually
exclusive (Ollmann et al., 1998). In addition, ASIP functions
as an inverse agonist to decrease basal MC1R signaling and
inhibit eumelanogenesis (Lu et al., 1994; Wilson et al., 1995).
Although ASIP’s primary sequence has no similarities to either
ACTH or α-MSH, it binds to MC1R with almost equal affinity
(Siegrist et al., 1996). ASIP’s cysteine rich C-terminal region binds
to MC1R via an octaloop structure with four residues that are
homologous to other melanocortin ligands (Ollmann et al., 1998;
Tota et al., 1999; McNulty et al., 2005). The C-terminal region of
ASIP is both necessary and sufficient for its effect at MC1R, and
the C-terminus alone can function as a competitive antagonist
to melanocortins at melanocortin receptors (Ollmann and Barsh,
1999).
Agouti signaling protein was known to promote a
pheomelanotic coat phenotype before it was determined to
be a direct ligand of MC1R. It is expressed in the dermal
papilla of the hair follicle where it functions as a paracrine
signal to regulate hair color (Millar et al., 1995). In the fur of
a variety of animals, the agouti locus is expressed transiently
to create alternating bands of pheomelanin and eumelanin on
the hair shaft which results in improved camouflage (Tamate
and Takeuchi, 1984). Canonically, ASP (the murine homolog
of the human ASIP) is secreted locally only at the hair follicle,
however, there are multiple murine models with varying coat
phenotypes dependent upon altered agouti expression. For
example, mice with the lethal yellow mutation (Ay), a dominant
gain of function mutation resulting in ectopic and ubiquitous
ASP expression, have a yellow/blonde coat color and are obese
with hyperinsulinemia due to binding of the overexpressed ASP
to MC4R (Takeuchi et al., 1989; Bultman et al., 1992; Robbins
et al., 1993; Duhl et al., 1994a,b; Michaud et al., 1994).
The ability of ASIP to promote a pheomelanotic phenotype
is dependent upon a functional MC1R, and ASIP had no effect
on MC1R with constitutive activity or loss of function (Ollmann
et al., 1998; Abdel-Malek et al., 2001). Treatment with ASIP
inhibits α-MSH binding to MC1R preventing α-MSH induced
cAMP production and tyrosinase, tyrosine related proteins 1 and
2, and MITF expression suppressing melanogenesis (Aberdam
et al., 1998). ASIP’s inhibitory effect on pigment production,
however, is seen with or without concomitant stimulation
with α-MSH suggesting that the effects of ASIP at MC1R
are not completely explained via preventing α-MSH binding
(Graham et al., 1997). Treatment of primary murine or human
melanocytes or melanoma cell lines with ASIP caused a decrease
in eumelanosomes and an inhibition of pigmentation (Hunt
and Thody, 1995; Sakai et al., 1997), and binding of ASIP to
wild-type MC1R leads to decreased basal tyrosinase activity and
decreased tyrosinase and tyrosinase related protein 1, 2, and
3 levels preventing eumelanogenesis (Sakai et al., 1997; Abdel-
Malek et al., 2001).
Treatment with agouti also affects additional MC1R signaling
pathways including NER, proliferation, and migration.
Concomitant stimulation with ASIP and α-MSH abrogated
α-MSH’s acceleration of NER following UV treatment (Jarrett
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FIGURE 7 | Melanocortin synthesis through proopiomelanocortin (POMC) processing. Melanocortins are derived from the proopiomelanocortin (POMC)
precursor peptide that is cleaved into functional peptide fragments by a pair of serine protease pro-protein convertases, PC1 and PC2. PC1 cleaves POMC into four
subunits including an n-terminal region from which γ-MSH is derived, adrenocorticotropic hormone (ACTH) and β-lipotropin (β-LPH) from which γ-LPH, β-MSH and
β-endorphin are generated by PC2 cleavage. α-MSH represents the first 13 amino acids of ACTH and is dependent on PC2 activity for its synthesis.
et al., 2014, 2015), decreased basal DNA repair kinetics in a dose
dependent manner and decreased basal ATR phosphorylation
at S435 in primary melanocytes (Jarrett et al., 2015). Consistent
with inhibition of MC1R signaling, treatment with ASIP leads
to a decrease in proliferation in a mouse melanoma cell line
(Siegrist et al., 1996) and an increase in melanocyte migration
(Le Pape et al., 2009).
ASP functions with two major accessory proteins: attractin
and mahogunin. Attractin is encoded by the Atrn gene and is
a large single transmembrane protein (Gunn et al., 1999; Nagle
et al., 1999) with an ectodomain that binds the amino terminus
of ASP (He et al., 2001) and is absolutely required for ASP
signaling in vivo. Although it is unknown whether attractin,
ASP, and Mc1r form a complex, mice without a functional
attractin protein are unresponsive to ASP signaling suggesting
attractin is required for ASP function at Mc1r. Mahogunin is
encoded by the Mgrn1 gene and is an intracellular protein that
functions as an E3 ubiquitin ligase (Phan et al., 2002; He et al.,
2003a,b).
Mutations in murine Atrn or Mgrn1 (formerly the mahogany
and mahoganoid mutations, respectively) are associated with
eumelanotic phenotypes similar to that seen in either a
mutation causing loss of function Agouti mutations or a
gain of function Mc1r mutation (Lane and Green, 1960).
Mutations in Atrn or Mgrn1 have no effect on plasma
α-MSH or ACTH levels, however, they do interfere with
agouti signaling and prevent it from binding to MC1R
effectively thereby resulting in a darkened coat color (Miller
et al., 1997). The interaction between attractin, mahogunin,
and ASP are unclear, however, a recent study suggests
that attractin and mahogunin mediated ASIP signaling is
cAMP independent, however, the cAMP dependent ASIP
signaling requires neither attractin nor mahogunin (Hida et al.,
2009).
Beta Defensin 3 (βD3)
The defensins are a group of antimicrobial peptides that link
innate and adaptive immune responses. They are small cationic
amphiphilic proteins composed of 30–40 amino acids (Boman,
1995; McCray and Bentley, 1997; De Lucca and Walsh, 1999;
Schneider et al., 2005) (Kesting et al., 2010) that target gram
positive and gram negative bacteria in addition to fungi (Garcia
et al., 2001; Schneider et al., 2005; Arnett and Seveau, 2011) by
binding to negatively charged membrane components (Schneider
et al., 2005). Although there are two major classes of defensins,
α and β (Schneider et al., 2005), only the β-defensins have
been identified in the skin (Bensch et al., 1995; Weinberg
et al., 1998; Huttner and Bevins, 1999; Schroder and Harder,
1999). Although βD1, βD2, and βD3 are all expressed in the
skin, βD3 appears to be unique in its ability to bind the
MC1R and influence melanocyte physiology (e.g., mammalian
coat color). βD3 is synthesized by keratinocytes in the spinous
and granular layers (Sawamura et al., 2005) and functions in
a paracrine manner by binding to MC1R on interdigitating
melanocytes (Harder et al., 2001; Garcia-Borron et al., 2005;
Candille et al., 2007) via electrostatic interactions (Nix et al.,
2013).
Clarence Cook Little was the first to demonstrate that
the dominant inheritance of black coat color in dogs was
independent of MC1R mutations and suggested that the color
was due to an unusual allele of agouti (Little, 1957; Candille
et al., 2007). However, Candille et al. (2007) identified the locus
responsible for Little’s observation as CBD103 (β defensin 103),
the canine homolog of βD3, rather than an agouti variant. Indeed,
overexpression of β defensin 103 and its subsequent binding
to MC1R inhibited interactions between ASIP and MC1R,
preventing the dogs from developing a blonde coat (Candille
et al., 2007). The ability of βD3 homologs to promote mammalian
black coat color requires a functional MC1R protein, showing β
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defensin 103’s effects are mediated by interactions with MC1R
rather than other melanocyte surface receptors (Nix et al., 2013).
Although regulation of βD3 following inflammatory stimuli
is established, its regulation in keratinocytes following exposure
to UV radiation is not well-characterized. βD3 expression is
induced in keratinocytes in the setting of inflammation or wound
formation (Kesting et al., 2010) and is mediated by inflammatory
cytokines including TNFα, IL-7, and IL-1β (Harder et al., 2001).
In contrast, neither TNFα nor IL-17 influence POMC or ASIP
expression, suggesting βD3 may be independently regulated
compared to the other melanocortins and that inflammatory-
mediated pigment changes may be βD3-dependent (Wang et al.,
2013). UVB radiation, which induces POMC gene expression
both in vivo and in vitro, has variable effects on βD3 induction,
depending upon the experimental model. In vivo exposure of
adult skin to UVB radiation led to increases in βD3 gene and
protein expression (Glaser et al., 2009), however, UV exposure
of ex vivo neonatal skin explants did not induce βD3 expression
suggesting that βD3 up-regulation following UVB exposure may
require recruitment of additional cell types, potentially cytokine-
producing immune cells, to the skin (Wolf Horrell and D’Orazio,
2014).
Multiple reports have demonstrated that βD3 binds MC1R.
In MC1R-transfected human embryonic kidney cells (HEK293),
βD3 functioned as a weak agonist and promoted cAMP
accumulation and MAP kinase activation (Beaumont et al.,
2012). However, in MC1Rwt primary melanocytes or in human
melan-a melanocytes, βD3 acted as a neutral MC1R antagonist,
exerting little influence on cellular cAMP levels independently
but preventing MSH and ASIP binding to MC1R (Swope et al.,
2012; Nix et al., 2013). Similarly, Candille et al. (2007) found
evidence that the canine homolog CBD103 functioned as a
neutral MC1R antagonist . Finally, we found that βD3 inhibited
α-MSH-induced generation of pS435-ATR and enhancement of
DNA repair (Jarrett et al., 2015). Thus most available data support
the hypothesis that βD3 acts as a neutral MC1R antagonist.
Importantly, regardless of experimental system, βD3 is unable
prevent the induction of cAMP and downstream melanocyte
differentiation pathways (e.g., pigment induction) by the direct
adenylyl cyclase activating drug forskolin confirming that βD3
functions at the level of the MC1R rather than by inhibiting the
adenylyl cyclase enzyme or other downstream MC1R signaling
event (Swope et al., 2012).
TARGETING THE
MELANOCORTIN-MC1R AXIS
The MC1R gene is a highly polymorphic genetic locus and
inherited defects in MC1R function are common among fair-
skinned, UV-sensitive and melanoma-prone persons. Indeed,
there may be up to 6–8 million Americans harboring double
allele polymorphisms and millions more being hemizygous
for MC1R (Kennedy et al., 2001). Individuals with defective
MC1R signaling are prone to melanoma and other UV induced
skin cancers not only because their skin is under-melanized
but also because they have a blunted melanocytic DNA
repair response. Because MC1R-mediated UV protection and
melanoma resistance is proportional to the robustness of the
cAMP response downstream of MC1R signaling and a variety
of pharmacologic strategies exist to impact cAMP, it might be
possible to exploit MC1R signaling as a UV- and melanoma-
preventive strategy. For example, topical application of either
forskolin, a direct activator of adenylyl cyclase, or rolipram,
a phosphodiesterase inhibitor, potently rescued eumelanin
production in pheomelanotic Mc1r-defective C57BL/6 animals
and protected the skin against UV damage (D’Orazio et al.,
2006; Khaled et al., 2010). Similarly, topical forskolin promoted
clearance of UV photoproducts in the skin (Jarrett et al.,
2014). These proof-of-principle studies indicate that beneficial
effects of MC1R signaling can be induced by pharmacologic
manipulation cAMP levels in the skin. Topical application of
agents that induce cAMP production or prevent its clearance,
while effective, lacks melanocyte specificity and off-target effects
must be considered before this approach can be deemed safe
or appropriate for translational use. Melanocortin analogs under
development offer a more targeted approach (Abdel-Malek et al.,
2006), but their efficacy is dependent on expression of functional
MC1R and therefore individuals with homozygous or compound
heterozygous MC1R defects may not benefit from these agents.
Although there is clearly a need for much more investigation into
the mechanisms, feasibility and consequences of pharmacologic
MC1R targeting, the melanocortin-MC1R signaling axis may
prove to be a useful target for rational development of novel
UV-resistance and melanoma-preventive strategies.
Therapeutic Implications and
Perspectives
Taking into account the abundance of data linking MC1R
function to the vigor of melanocytic UV physiologic responses,
it is clear that the MSH-MC1R signaling axis represents a
critical innate UV-protective mechanism in the skin. Whereas
its importance was first appreciated based on its contribution
to melanin biosynthesis, more recent studies have documented
a direct link between cAMP signaling and melanocyte genomic
stability. It is now well-established that melanoma ranks among
the highest of human tumors with respect to somatic mutational
load (Hodis et al., 2012; Lawrence et al., 2014) and that UV
signature mutations account for the majority of melanoma-
associated mutations (Shain et al., 2015). Epidermal melanocytes,
the precursor cells that give rise to melanoma, are long-lived
cells that because of their position in the skin, must cope with
intermittent UV damage. In addition to overall UV dose and
the pattern of UV injury (acute vs. chronic), it is likely that
UV mutagenesis (and ultimately melanoma incidence) will be
heavily influenced by the efficiency by which melanocytes repair
nuclear UV photodamage. MC1R-defective individuals, because
of their tendency to be undermelanized (which allows more UV
to penetrate into the basal layer of the epidermis) and because
they lack the DNA repair “boost” that an effective MSH-MC1R
axis yields, should accumulate more UV mutagenesis over time
and would therefore be at higher risk for melanoma as a result.
Pharmacologic “rescue” of cAMP signaling would protect such
individuals by enhancing pigment production and by promoting
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genomic stability. Intriguingly, MC1R function might also
predict therapeutic response to immune-based anti-melanoma
therapies. Though this has yet to be formally tested, it is possible
that melanomas with higher somatic mutational burdens (as
might occur in the MC1R-defective state) might respond better to
immune checkpoint blockade because they would express more
mutated proteins, any one of which might be recognized as a
tumor-associated antigen for cytotoxic lymphocytes. Because of
its central regulatory role for a host of melanocyte physiological
responses, the MC1R signaling pathway is emerging as an ever-
increasingly important pharmacologic target in preventing or
treating melanoma.
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